ADENO-ASSOCIATED VIRUS TYPE 6 IS RETROGRADELY TRANSPORTED IN THE NON-HUMAN PRIMATE BRAIN

We recently demonstrated that axonal transport of adeno-associated virus (AAV) is serotype-dependent. Thus, AAV serotype 2 (AAV2) is anterogradely transported (e.g., from cell bodies to nerve terminals) in both rat and non-human primate (NHP) brain. In contrast, AAV serotype 6 (AAV6) is retrogradely transported from terminals to neuronal cell bodies in the rat brain. However, the directionality of axonal transport of AAV6 in the NHP brain has not been determined. In this study, two Cynomolgus macaques received an infusion of AAV6 harboring green fluorescent protein (GFP) into the striatum (caudate and putamen) by magnetic resonance (MR)-guided convection-enhanced delivery. One month after infusion, immunohistochemical staining of brain sections revealed a striatal GFP expression that corresponded well with MR signal observed during gene delivery. As shown previously in rats, GFP expression was detected throughout the prefrontal, frontal and parietal cortex, as well as the substantia nigra pars compacta and thalamus, indicating retrograde transport of the vector in NHP. AAV6-GFP preferentially transduced neurons, although a few astrocytes were also transduced. Transduction of non-neuronal cells in the brain was associated with the upregulation of the major histocompatibility complex-II and lymphocytic infiltration as previously observed with AAV1 and AAV9. This contrasts with highly specific neuronal transduction in the rat brain. Retrograde axonal transport of AAV6 from a single striatal infusion permits efficient transduction of cortical neurons in significant tissue volumes that otherwise would be difficult to achieve.

[1]  T. Powell,et al.  The cortico-striate projection in the monkey. , 1970, Brain : a journal of neurology.

[2]  M. Sands,et al.  Intravitreal Gene Therapy Reduces Lysosomal Storage in Specific Areas of the CNS in Mucopolysaccharidosis VII Mice , 2003, The Journal of Neuroscience.

[3]  K. Bankiewicz,et al.  Guided delivery of adeno-associated viral vectors into the primate brain. , 2012, Advanced drug delivery reviews.

[4]  Chunling Tang,et al.  Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. , 2003, Current opinion in drug discovery & development.

[5]  D. Young,et al.  Nucleic Acid-Based Therapy Approaches for Huntington's Disease , 2012, Neurology research international.

[6]  D. Yin,et al.  Efficient gene therapy-based method for the delivery of therapeutics to primate cortex , 2009, Proceedings of the National Academy of Sciences.

[7]  P. Goldman-Rakic,et al.  Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  J. Cummings,et al.  Huntington's disease. , 1997, The Psychiatric clinics of North America.

[9]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[10]  Gabriele Mittermeyer,et al.  Axonal transport of adeno-associated viral vectors is serotype-dependent , 2012, Gene Therapy.

[11]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[12]  J. F. Wright,et al.  Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Paul S Larson,et al.  Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  Ryuta Saito,et al.  Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. , 2005, Journal of neurosurgery.

[15]  M. Fiandaca,et al.  Image-guided convection-enhanced delivery platform in the treatment of neurological diseases , 2011, Neurotherapeutics.

[16]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Bankiewicz,et al.  Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  B. Davidson,et al.  Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. , 2008, Human gene therapy.

[19]  Yoji Yamashita,et al.  The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  J. Bringas,et al.  Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. , 2006, Human gene therapy.

[21]  L. Villarreal,et al.  Adeno-associated virus vectors can be efficiently produced without helper virus , 1998, Gene Therapy.

[22]  N. L. Chamberlin,et al.  Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS , 1998, Brain Research.